Cover Image

TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer

Gatipotuzumab is a fully humanized antibody which was designed to detect a cancer-specific glyco-modification of MUC1 (termed ‘TA-MUC1’) and which was optimized to effectively trigger antibody-dependent-cell-mediated cytotoxicity (ADCC) in cancer cells. Clinical trials investigating therapeutic effi...

Full description

Saved in:
Bibliographic Details
Main Authors: Heublein, Sabine (Author) , Friese, Klaus (Author) , Kost, Bernd (Author) , Marmé, Frederik (Author) , Kuhn, Christina (Author) , Mahner, Sven (Author) , Dannecker, Christian (Author) , Mayr, Doris (Author) , Jeschke, Udo (Author) , Vattai, Aurelia (Author)
Format: Article (Journal)
Language:English
Published: 30 July 2018
In: Journal of cancer research and clinical oncology
Year: 2018, Volume: 144, Issue: 10, Pages: 1899-1907
ISSN:1432-1335
DOI:10.1007/s00432-018-2706-5
Online Access:Verlag, Volltext: https://doi.org/10.1007/s00432-018-2706-5
Get full text
Author Notes:Sabine Heublein, Klaus Friese, Bernd Kost, Frederik Marmé, Christina Kuhn, Sven Mahner, Christian Dannecker, Doris Mayr, Udo Jeschke, Aurelia Vattai
Description
Summary:Gatipotuzumab is a fully humanized antibody which was designed to detect a cancer-specific glyco-modification of MUC1 (termed ‘TA-MUC1’) and which was optimized to effectively trigger antibody-dependent-cell-mediated cytotoxicity (ADCC) in cancer cells. Clinical trials investigating therapeutic efficacy of this antibody have been published recently. The current analysis aimed to determine whether TA-MUC1—as detected by Gatipotuzumab—is expressed in cervical cancer tissue and whether binding of Gatipotuzumab is associated with clinico-pathological variables including recurrence free (RFS) and overall survival (OS).
Item Description:Gesehen am 14.01.2020
Physical Description:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-018-2706-5

Similar Items